Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply

Bibliographic Details
Main Authors:	Jr, W, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M
Format:	Journal article
Published:	2012

Similar Items

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
by: Wells, SA, et al.
Published: (2012)

Reply to J.-F. Chatal et al.
by: Wells Jr, SA, et al.
Published: (2012)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
by: Nils Degrauwe, et al.
Published: (2012-06-01)

Calcitonin receptor expression in medullary thyroid carcinoma
by: Virginia Cappagli, et al.
Published: (2017-09-01)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer
by: Ecem Bostan, et al.
Published: (2022-09-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
by: Fallahi P, et al.
Published: (2019-08-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

CALCITONINS ROLE - REPLY
by: Kanis, J, et al.
Published: (1977)

Metastatic Medullary Thyroid Carcinoma with Normal Serum Calcitonin Levels
by: Tania Tofail, MRCP, et al.
Published: (2018-11-01)

Serum calcitonin negative Medullary thyroid carcinoma
by: Welsing Ellen, et al.
Published: (2006-12-01)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
by: Ai Matsui, et al.
Published: (2022-01-01)

In-situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma.
by: Boultwood, J, et al.
Published: (1990)

Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma
by: Wenliang Yue, et al.
Published: (2022-11-01)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
by: Heymach, J, et al.
Published: (2008)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
by: Pierpaolo Trimboli, et al.
Published: (2018-05-01)

Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin
by: Bo Wang, et al.
Published: (2024-10-01)

The role of calcitonin in the preoperative stage as the predictor of medullary thyroid cancer metastases
by: Volodymyr Palamarchuk, et al.
Published: (2021-12-01)

Kinase inhibitors for advanced medullary thyroid carcinoma
by: Martin Schlumberger, et al.
Published: (2012-01-01)

Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence?
by: Huguet, I, et al.
Published: (2013)

Early calcitonin levels in medullary thyroid carcinoma: Prognostic role in patients without distant metastases at diagnosis
by: Clotilde Sparano, et al.
Published: (2023-02-01)

Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma
by: Fengli Guo, et al.
Published: (2024-05-01)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
by: LI Rui, LIU Zhuoran, YAN Jiqi
Published: (2022-06-01)

Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
by: Il Youb Jeong, et al.
Published: (2024-08-01)

The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer
by: Yingtong Hou, et al.
Published: (2024-07-01)

Cytodiagnosis of medullary carcinoma thyroid- role of FNAC and serum calcitonin- A case report
by: Majed B Momin, et al.
Published: (2018-01-01)

False positive results using calcitonin as a screening method for medullary thyroid carcinoma
by: Rafael Loch Batista, et al.
Published: (2013-01-01)

Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
by: Claudio Gambardella, et al.
Published: (2019-05-01)

Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma
by: Hyunju Park, et al.
Published: (2021-10-01)

Nephrotic Syndrome as a Complication of Systemic Calcitonin Amyloidosis From Long-Standing Metastatic Medullary Thyroid Cancer
by: Samantha M. Siskind, MD, et al.
Published: (2024-11-01)

Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study
by: Zan Jiao, et al.
Published: (2022-12-01)

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
by: Hanrahan, E, et al.
Published: (2009)

Calcitonin testing in patients with thyroid nodules for screening medullary thyroid carcinoma: a “gray zone”
by: N. V. Severskaya, et al.
Published: (2022-08-01)

Selective use of vandetanib in the treatment of thyroid cancer
by: Fallahi P, et al.
Published: (2015-07-01)

Biophysical and computational characterization of vandetanib–lysozyme interaction
by: Kabir, Md Zahirul, et al.
Published: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
by: Abdul Qadir, MPhil, et al.
Published: (2023-10-01)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
by: Jade Cury-Martins, et al.
Published: (2018-10-01)

Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)

Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
by: Begümhan Demir Gündoğan, et al.
Published: (2021-09-01)

Measurement of calcitonin and cea in the needle washout fluid from thyroid nodule for the diagnosis of medullary thyroid carcinoma
by: N. V. Severskaya, et al.
Published: (2023-11-01)

Lymph Node Metastases of Medullary Thyroid Cancer: Role of Calcitonin in the Washout Fluid of Fine-Needle Aspiration
by: Bernardo Marques, et al.
Published: (2020-01-01)